Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
European Journal of Cancer · 2023
DOI: 10.1016/j.ejca.2023.04.008 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Anne Zaremba und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Essen, Essen, Germany. Electronic address: anne.zaremba@uk-essen.de. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Essen, Essen, Germany. Electronic address: anne.zaremba@uk-essen.de.
- Department of Dermatology, Elbe Clinic Buxtehude, Buxtehude, Germany.
- Department of Dermatology, Hannover Medical School, Skin Cancer Centre Hannover, Hannover, Germany.
- Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases, Dresden, Germany; Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; Nation…
- Saarland University Medical Center, Department of Dermatology, Homburg, Saarland, Germany.
- Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Zaremba, A., Mohr, P., Gutzmer, R., Meier, F., Pföhler, C., Weichenthal, M., Terheyden, P., Forschner, A., Leiter, U., Ulrich, J., Utikal, J., Welzel, J., Kaatz, M., Gebhardt, C., Herbst, R., Sindrilaru, A., Dippel, E., Sachse, M., Meiss, F., …, & Zimmer, L. (2023). Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.04.008
Vancouver
Zaremba A, Mohr P, Gutzmer R, Meier F, Pföhler C, Weichenthal M, et al. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.04.008
BibTeX
@article{Zaremba2023,
author = {Zaremba, Anne and Mohr, Peter and Gutzmer, Ralf and Meier, Friedegund and Pföhler, Claudia and Weichenthal, Michael and Terheyden, Patrick and Forschner, Andrea and Leiter, Ulrike and Ulrich, Jens and Utikal, Jochen and Welzel, Julia and Kaatz, Martin and Gebhardt, Christoffer and Herbst, Rudolf and Sindrilaru, Anca and Dippel, Edgar and Sachse, Michael and Meiss, Frank and Heinzerling, Lucie and Haferkamp, Sebastian and Weishaupt, Carsten and Löffler, Harald and Kreft, Sophia and Griewank, Klaus and Livingstone, Elisabeth and Schadendorf, Dirk and Ugurel, Selma and Zimmer, Lisa},
title = {Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG},
journal = {European Journal of Cancer},
year = {2023},
doi = {10.1016/j.ejca.2023.04.008}
}
EUVIMED